Q2 2019

Source filing unavailable

Q2 2019 · —

Revenue—

Net Income

-$6.85M

N/M vs Q2 2018

EPS Diluted

-$3.42

N/M vs Q2 2018

Operating Income-$7,019,000—

Operating Cash Flowderived-$4,472,000—

Free Cash Flowderived

Same quarter

Metric	Q2 2019	Q2 2018
Net Income	-$6.85M	-$4.44M
EPS Diluted	-$3.42	-$3.01

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Korro Bio, Inc. · CIK 1703647 · Engraved from SEC EDGAR